Synthesis and Characterization of YYGSR-NH2 as a Chemical Starting Poin for Thyroid Theranostic Radiopharmaceutical Development
DOI:
https://doi.org/10.35451/jfm.v9i1.3856Keywords:
YYGSR-NH₂, sintesis peptida, RP-HPLC, spektrometri massa, radiofarmaka theranostik, Solid Phase Peptide Synthesis (SPPS)Abstract
Thyroid cancer is an endocrine malignancy that still requires the development of more targeted diagnostic and therapeutic approaches. Peptides are promising chemical platforms for radiopharmaceutical development because they can be synthesized in a controlled manner and chemically modified. This study aimed to synthesize and characterize YYGSR-NH₂ as a chemical starting point for thyroid theranostic radiopharmaceutical development. YYGSR-NH₂ was synthesized using Fmoc-solid phase peptide synthesis on Fmoc-Rink amide resin through sequential coupling of Arg, Ser, Gly, Tyr, and Tyr residues. Deprotection was performed using 20% piperidine in DMF, while coupling was carried out using HATU, HOAt, and DIPEA. The peptide was cleaved from the resin using TFA/TIS/H₂O, purified by semi-preparative RP-HPLC, and characterized using analytical RP-HPLC and time-of-flight mass spectrometry. The resin loading obtained was 0.546 mmol/g, with an average crude product mass of 0.4739 g. Semi-preparative HPLC showed several components with major peaks at retention times of approximately 12–14 min. Analytical HPLC showed two peaks at retention times of 1.315 and 26.412 min, with relative areas of 96.31% and 3.69%, respectively. Mass spectrometry showed a dominant ion at m/z 644.3157, which was consistent with the theoretical [M+H]⁺ ion of YYGSR-NH₂. Based on these results, YYGSR-NH₂ was successfully synthesized and its molecular identity was confirmed by mass spectrometry, supporting its use as a chemical starting point for further development of thyroid theranostic radiopharmaceuticals.
Downloads
References
[1] International Agency for Research on Cancer. Global Cancer Observatory: Thyroid Cancer Fact Sheet, GLOBOCAN 2022. Lyon: IARC; 2024.
[2] Roseland ME, Dewaraja YK, Wong KK. Advanced imaging and theranostics in thyroid cancer. Curr Opin Endocrinol Diabetes Obes. 2022;29(5):456–465. doi:10.1097/MED.0000000000000740.
[3] Eilsberger F, Pfestroff A. Theranostics in Thyroid Cancer. PET Clin. 2021 Jul;16(3):375-382. doi: 10.1016/j.cpet.2021.03.007. PMID: 34053581.
[4] Holik HA, Ibrahim FM, Elaine AA, Putra BD, Achmad A, Kartamihardja AHS. The chemical scaffold of theranostic radiopharmaceuticals: radionuclide, bifunctional chelator, and pharmacokinetics modifying linker. Molecules. 2022;27(10):3062. doi:10.3390/molecules27103062.
[5] Nock BA, Kanellopoulos P, Joosten L, Mansi R, Maina T. Peptide radioligands in cancer theranostics: agonists and antagonists. Pharmaceuticals. 2023;16(5):674. doi:10.3390/ph16050674.
[6] Wang L, Wang N, Zhang W, Cheng X, Yan Z, Shao G, et al. Therapeutic peptides: current applications and future directions. Signal Transduct Target Ther. 2022;7:48. doi:10.1038/s41392-022-00904-4.
[7] Iwamoto Y, Robey FA, Graf J, Sasaki M, Kleinman HK, Yamada Y, Martin GR. YIGSR, a synthetic laminin pentapeptide, inhibits experimental metastasis formation. Science. 1987;238(4830):1132–1134. doi:10.1126/science.2961059.
[8] Koliakos G, Trontzos C, Kouzi-Koliakos K, Kanellaki M, Grammaticos P. Lung carcinoma imaging using a synthetic laminin derivative radioiodinated peptide YIGSR. J Nucl Med. 1997;38(12):1940–1944.
[9] Mendonça FF, Sobral DV, Durante ACR, Miranda ACC, Mejia J, Faria DP, et al. Assessment of bioactive peptides derived from laminin-111 as prospective breast cancer-targeting agents. Amino Acids. 2024;56(1):1. doi:10.1007/s00726-023-03379-x.
[10] Sharma K, Sharma KK, Sharma A, Jain R. Peptide-based drug discovery: current status and recent advances. Drug Discov Today. 2023;28(2):103464. doi:10.1016/j.drudis.2022.103464.
[11] Hansen PR, Oddo A. Fmoc solid-phase peptide synthesis. Methods Mol Biol. 2024;2821:33–55. doi:10.1007/978-1-0716-3914-6_3.
[12] Sharma N, Kukreja D, Giri T, Kumar S, Shah RP. Synthetic pharmaceutical peptides characterization by chromatography principles and method development. J Sep Sci. 2022;45(13):2200–2216. doi:10.1002/jssc.202101034.
[13] Maharani R, Muhajir MI, Dirgantara JM, Rasyid H, Kusumawati Y, Kartikowati CW, Umaningrum D. Synthesis, antimicrobial activity, and in silico mechanistic study of linear bacicylin analogs. Arabian J Chem. 2025;18(8):3282024. doi:10.25259/AJC_328_2024.
[14] Maharani R, Firdausi A, Mayanti T, Harneti D, Nurlelasari, Ishmayana S, et al. Total synthesis of a reversed-bacicyclin using a combination of solid- and solution-phase methods. Indones J Chem. 2022;22(4):1061–1069. doi:10.22146/ijc.72956.
[15] Aluri K, Basavoju S, Rangisetty J, Pullagurla MR, Pitta BR. Synthesis of diastereomerically pure cetrorelix acetate by using Fmoc solid-phase peptide synthesis strategy: a commercially viable approach. J Pept Sci. 2025;31:e70030. doi:10.1002/psc.70030.
[16] Lian Z, Wang N, Tian Y, Huang L. Characterization of synthetic peptide therapeutics using liquid chromatography-mass spectrometry: challenges, solutions, pitfalls, and future perspectives. J Am Soc Mass Spectrom. 2021;32(8):1852–1860. doi:10.1021/jasms.0c00479.
[17] Duengo S, Muhajir MI, Hidayat AT, Musa WJA, Maharani R. Epimerisation in peptide synthesis. Molecules. 2023;28(24):8017. doi:10.3390/molecules28248017.
[18] Mthembu SN, Chakraborty A, Schönleber R, Albericio F, de la Torre BG. Morpholine, a strong contender for Fmoc removal in solid-phase peptide synthesis. J Pept Sci. 2024;30(2):e3538. doi:10.1002/psc.3538.
[19] Yan C, Fyfe C, Minty L, Barrington H, Jamieson C, Reid M. Computer vision as a new paradigm for monitoring of solution and solid phase peptide synthesis. Chem Sci. 2023;14:11872–11880. doi:10.1039/D3SC01383A.
[20] Abdildinova A, Kurth MJ, Gong YD. Heterocycles as a peptidomimetic scaffold: solid-phase synthesis strategies. Pharmaceuticals (Basel). 2021;14(5):449. doi:10.3390/ph14050449.
[21] Cheung MY, Bruce J, Euerby MR, Field JK, Petersson P. Investigation into reversed-phase chromatography peptide separation systems part V: establishment of a screening strategy for development of methods for assessment of pharmaceutical peptides' purity. J Chromatogr A. 2022;1668:462888. doi:10.1016/j.chroma.2022.462888.
[22] Petersson P, Buckenmaier S, Euerby MR, Stoll DR. A strategy for assessing peak purity of pharmaceutical peptides in reversed-phase chromatography methods using two-dimensional liquid chromatography coupled to mass spectrometry. Part I: Selection of columns and mobile phases. J Chromatogr A. 2023;1693:463874. doi:10.1016/j.chroma.2023.463874.
[23] Stoll DR, Sylvester M, Euerby MR, Buckenmaier SMC, Petersson P. A strategy for assessing peak purity of pharmaceutical peptides in reversed-phase chromatography methods using two-dimensional liquid chromatography coupled to mass spectrometry. Part II: Development of second-dimension gradient conditions. J Chromatogr A. 2023;1693:463873. doi:10.1016/j.chroma.2023.463873.
[24] Chrone VG, Lorentzen A, Højrup P. Characterization of synthetic peptides by mass spectrometry. Methods Mol Biol. 2024;2821:83–89. doi:10.1007/978-1-0716-3914-6_7
[25] Gillings N, Hjelstuen O, Behe M, Decristoforo C, Elsinga PH, Ferrari V, et al. EANM guideline on quality risk management for radiopharmaceuticals. Eur J Nucl Med Mol Imaging. 2022;49(10):3353–3364. doi:10.1007/s00259-022-05738-4.
[26] Hooijman EL, Ntihabose CM, Reuvers TGA, Nonnekens J, Aalbersberg EA, van de Merbel JRJP, et al. Radiolabeling and quality control of therapeutic radiopharmaceuticals: optimization, clinical implementation and comparison of radio-TLC/HPLC analysis, demonstrated by [¹⁷⁷Lu]Lu-PSMA. EJNMMI Radiopharm Chem. 2022;7:29. doi:10.1186/s41181-022-00181-0.
[27] Nelson BJB, Krol V, Bansal A, Andersson JD, Wuest F, Pandey MK. Aspects and prospects of preclinical theranostic radiopharmaceutical development. Theranostics. 2024;14(17):6446–6470. doi:10.7150/thno.100339.
[28] Satapathy S, Bal C. Theranostic options for radioiodine-refractory differentiated thyroid carcinoma: recent advances, challenges, and road ahead. Front Endocrinol (Lausanne). 2022;13:924841. doi:10.3389/fendo.2022.924841
[29] Giovanella L, Deandreis D, Vrachimis A, Campennì A, Petranović Ovčariček P. Molecular imaging and theragnostics of thyroid cancers. Cancers (Basel). 2022;14(5):1272. doi:10.3390/cancers14051272.
[30] Campennì A, Siracusa M, Ruggeri RM. Oldie but goldie: the fundamental role of radioiodine in the management of thyroid cancer. J Clin Med. 2024;13(21):6400. doi:10.3390/jcm13216400.
[31] Umeno T, Fujihara M, Matsumoto S, Iizuka N, Usui K, Karasawa S. Quantitative and nondestructive colorimetric amine detection method for the solid-phase peptide synthesis as an alternative to the Kaiser test. Anal Chem. 2023;95(42):15803–15809. doi:10.1021/acs.analchem.3c03350.
[32] Terzani F, Wang C, Rostami S, Desmet R, Snella B, Sénéchal M, et al. Protocol for protein modification using oxalyl thioester-mediated chemoselective ligation. STAR Protoc. 2024;5(4):103390. doi:10.1016/j.xpro.2024.103390.
[33] Eissler S, Kley M, Bächle D, Loidl G, Meier T, Samson D. Substitution determination of Fmoc-substituted resins at different wavelengths. J Pept Sci. 2017;23:757–762. doi:10.1002/psc.3021.
[34] Noki S, Lastella L, Serban S, Basso A, Orosz G, de la Torre BG, Albericio F. Triethyl phosphate (TEP)–dimethylsulfoxide (DMSO), as a green solvent mixture for solid-phase peptide synthesis (SPPS). Green Chem Lett Rev. 2025;18(1):2438068. doi:10.1080/17518253.2024.2438068.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Dalifa Ramadhani, Pusva Sandra Dewi, Bilqis Nurganiyu
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright in each article is the property of the Author.
